Thus, by integrating other significant prognostic factors, such as tumour markers, the individual prognosis of patients can be better assessed.3 In clinical practice, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 are the most commonly used markers for the early diagnosis and monitoring of GC. This evidence concerns the gene CEACAM5 and gastric cancer.